Achieving Haemostasis
Strategies for the drug treatment of haemophilia and VWD depend on the risk of bleeding. For haemophilia, replacement FVIII is the treatment of choice for prophylaxis and acute treatment of bleeding Desmopressin may be preferred for patients with mild or moderate haemophilia A when FVIII can be raised to an appropriate therapeutic level; in such …
What is pharmacokinetics?
Pharmacokinetics is the science of what happens to drugs in the body (drug disposition). It uses mathematics to quantify the drug’s journey from absorption to distribution, metabolismand elimination and describes how these processes change over time and in relation to one another. This can get complicated – even incomprehensible to the average health professional – but a …
Ensuring the Safety of Medicines for Haemophilia
A medicine’s journey from laboratory bench to bedside is a highly regulated process – one that takes years. Trials involve thousands of people who take a compound that may or may not become a medicine and for which the risks are largely unknown. The safety of volunteers and patients who participate in these trials is …
EHL factor concentrates
Haemophilia is an X-linked inherited bleeding disorder characterised by reduced levels of Factor VIII or IX levels (haemophilia A and B) respectively [Shrivastava et al, 2013]. In its severe form (FVIII or IX <0.01IU/dl) haemophilia results in recurrent joint and muscle bleeds that predispose to arthropathy, muscle contracture and disability. Prophylaxis with clotting factor replacement …